Author Archives: Mary Chapman

China Approves SMA Treatment Spinraza for Most Patients

Spinraza (nusinersen) has been approved by China’s National Medical Product Administration (NMPA) for the treatment of the most common form of spinal muscular atrophy (SMA). Marketed by Biogen and increasingly available worldwide, Spinraza is the first approved treatment in China for SMA, a disease that results in progressively…

Cure SMA Campaign Promotes Early Diagnosis and Treatment

The Cure SMA educational campaign is designed to equip parents and healthcare professionals with the tools needed to recognize motor delays in spinal muscular atrophy (SMA) patients early, allowing infants and children to receive potentially life-saving treatment. Called SMArt Moves, the program cites the fact that Spinraza and…